These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 15299080)

  • 1. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model.
    Raben D; Bianco C; Damiano V; Bianco R; Melisi D; Mignogna C; D'Armiento FP; Cionini L; Bianco AR; Tortora G; Ciardiello F; Bunn P
    Mol Cancer Ther; 2004 Aug; 3(8):977-83. PubMed ID: 15299080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor.
    Solomon B; Hagekyriakou J; Trivett MK; Stacker SA; McArthur GA; Cullinane C
    Int J Radiat Oncol Biol Phys; 2003 Mar; 55(3):713-23. PubMed ID: 12573759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
    Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
    Bianco C; Tortora G; Bianco R; Caputo R; Veneziani BM; Caputo R; Damiano V; Troiani T; Fontanini G; Raben D; Pepe S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2002 Oct; 8(10):3250-8. PubMed ID: 12374696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
    Tortora G; Caputo R; Damiano V; Melisi D; Bianco R; Fontanini G; Veneziani BM; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2003 Apr; 9(4):1566-72. PubMed ID: 12684433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index.
    She Y; Lee F; Chen J; Haimovitz-Friedman A; Miller VA; Rusch VR; Kris MG; Sirotnak FM
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3773-8. PubMed ID: 14506170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Fontanini G; Cuccato S; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2001 May; 7(5):1459-65. PubMed ID: 11350918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway.
    Sumitomo M; Asano T; Asakuma J; Asano T; Horiguchi A; Hayakawa M
    Clin Cancer Res; 2004 Jan; 10(2):794-801. PubMed ID: 14760103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa).
    Huang SM; Li J; Armstrong EA; Harari PM
    Cancer Res; 2002 Aug; 62(15):4300-6. PubMed ID: 12154033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo.
    Naruse I; Ohmori T; Ao Y; Fukumoto H; Kuroki T; Mori M; Saijo N; Nishio K
    Int J Cancer; 2002 Mar; 98(2):310-5. PubMed ID: 11857424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.
    Raben D; Helfrich BA; Chan D; Johnson G; Bunn PA
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):37-46. PubMed ID: 11894012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.
    Blakey DC; Westwood FR; Walker M; Hughes GD; Davis PD; Ashton SE; Ryan AJ
    Clin Cancer Res; 2002 Jun; 8(6):1974-83. PubMed ID: 12060643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
    Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
    Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474.
    Shi W; Siemann DW
    In Vivo; 2005; 19(6):1045-50. PubMed ID: 16277020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmentation of radiation response with the vascular targeting agent ZD6126.
    Hoang T; Huang S; Armstrong E; Eickhoff JC; Harari PM
    Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1458-65. PubMed ID: 16488554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of tumor growth and tumor induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 in renal cell carcinoma.
    Asakuma J; Sumitomo M; Asano T; Asano T; Hayakawa M
    J Urol; 2004 Feb; 171(2 Pt 1):897-902. PubMed ID: 14713849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice.
    Goto H; Yano S; Zhang H; Matsumori Y; Ogawa H; Blakey DC; Sone S
    Cancer Res; 2002 Jul; 62(13):3711-5. PubMed ID: 12097279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.